Publication at First Faculty of Medicine |
2018
Abstract
Objective: Overview of available information on current vaccination options against HPV and possibilities for further development. Methods and results: Three prophylactic vaccines have been developed against HPV infection and are all now avaliable in Czech Repulbic; nonavalent (Gardasil 9), quadrivalent vaccine (Silgard) and bivalent vaccine (Cervarix).
Therapeutic vaccines, designed to induce regression of existing HPV-associated lesions, are in development and not yet clinically available. Conclusion: All three avaliable prophylactic vaccines show high efficacy in prevention of vaccine-specific HPV-type infection.
The highest degree of protection is achieved in the population of HPV-naive women.